Traders Buy High Volume of Genmab A/S Call Options (NASDAQ:GMAB)

Key Points

• Genmab call-option activity surged: Traders purchased 4,002 call options, 169% above the average daily volume of 1,487 contracts, signaling heightened bullish interest.
• Genmab shares fell $0.82 to $33.54 during midday trading, but the company recently exceeded quarterly expectations with $0.54 in EPS versus a $0.37 consensus and $1.16 billion in revenue.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $39.50; several firms recently raised their targets to between $40 and $43.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) saw unusually large options trading activity on Wednesday. Stock traders bought 4,002 call options on the stock. This is an increase of 169% compared to the average daily volume of 1,487 call options.

Genmab A/S Price Performance

Shares of NASDAQ GMAB traded down $0.82 during midday trading on Wednesday, hitting $33.54. 1,095,343 shares of the company's stock were exchanged, compared to its average volume of 1,955,105. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $35.43. The company has a market cap of $20.91 billion, a price-to-earnings ratio of 26.41, a PEG ratio of 1.96 and a beta of 0.83. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The business's fifty day moving average price is $29.18 and its two-hundred day moving average price is $27.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.12 billion. As a group, research analysts forecast that Genmab A/S will post 1.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GMAB. HC Wainwright raised their price target on Genmab A/S from $38.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, July 2nd. New Street Research set a $43.00 price objective on Genmab A/S in a report on Wednesday, July 22nd. TD Cowen upgraded Genmab A/S from a "hold" rating to a "buy" rating and raised their target price for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Truist Financial initiated coverage on Genmab A/S in a report on Wednesday, May 27th. They set a "buy" rating and a $40.00 target price for the company. Finally, Weiss Ratings upgraded shares of Genmab A/S from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $39.50.

Institutional Trading of Genmab A/S

A number of hedge funds have recently bought and sold shares of GMAB. CIBC Private Wealth Group LLC boosted its stake in shares of Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company's stock valued at $25,000 after purchasing an additional 616 shares in the last quarter. Osaic Holdings Inc. lifted its stake in shares of Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock valued at $33,000 after acquiring an additional 440 shares during the last quarter. V Square Quantitative Management LLC bought a new position in Genmab A/S during the 1st quarter worth approximately $34,000. NewEdge Advisors LLC lifted its position in Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company's stock valued at $38,000 after purchasing an additional 1,143 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its stake in shares of Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company's stock valued at $41,000 after purchasing an additional 780 shares during the period. Institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source